期刊文献+

肝细胞癌冷冻消融术后早期复发的危险因素 被引量:3

Risk factors for early recurrence after cryoablation for hepatocellular carcinoma
下载PDF
导出
摘要 目的:探讨肝细胞癌(hepatocellular carcinoma,HCC)患者冷冻消融术后影响早期复发的相关危险因素.方法:回顾分析90例直径≤5.0cm的HCC行冷冻消融治疗后复发的患者的临床资料,分析影响冷冻消融术后早期复发的危险因素.结果:本组患者随访8-47(平均随访时间21.9±10.1)mo,共有57例(63.3%)早期复发(≤2年),33例(36.7%)晚期复发(>2年).早期复发组与晚期复发组复发后的中位生存时间分别为21mo和36mo,二者具有显著差异(P<0.05).单因素分析结果显示,术前血清甲胎蛋白(AFP)>200μg/L、乙型肝炎病毒(HBV)DNA>5log10copies/mL、肿瘤最大直径>3cm、肿瘤邻近大血管(直径≥6mm)是HCC冷冻消融术后早期复发的危险因素(P<0.05);多因素分析显示术前HBV-DNA>5log10 copies/mL、肿瘤最大直径>3cm、肿瘤邻近大血管是HCC冷冻消融术后早期复发的独立影响因素(P<0.05).结论:冷冻消融术后早期复发影响术后远期生存.术前HBVDNA>5log10 copies/mL、肿瘤最大直径>3cm、肿瘤邻近大血管的HCC患者在冷冻消融术后应警惕早期复发,可根据患者的不同特点采用个体化辅助治疗方案. AIM:To investigate risk factors for early recurrence after cryoablation for hepatocellular carcinoma(HCC).METHODS:The clinical data for 90 HCC patients with recurrence after cryoablation were analyzed retrospectively.Risk factors associated with tumor early recurrence were assessed.RESULTS:During a median follow-up of 21.9 mo ± 10.1 mo(range,8 to 47 mo),early recurrences were observed in 57 out of 90 patients(63.4%) and late recurrences in 29 patients(32.2%).The median survival time was significant lower in the early recurrence group than in the late recurrence group(21 mo vs 36 mo,P 0.05).Univariate analysis demonstrated that risk factors associated with early recurrence after cryoablation for HCC were preoperative serum α-fetoprotein(AFP) level 200 μg/L,hepatitis B virus(HBV) DNA level 5 log10 copies/mL,maximum tumor diameter 3 cm,and adjacency of the tumor to large blood vessels(diameter ≥ 6 mm).Multivariate analysis showed that preoperative HBV DNA level 5 log10 copies/mL,maximum tumor diameter 3 cm,and adjacency of the tumor to large blood vessels were independent risk factors for early recurrence after cryoablation for HCC(all P 0.05).CONCLUSION:Preoperative HBV DNA level 5 log10 copies/mL,maximum tumor diameter 3 cm and adjacency of the tumor to large blood vessels are independent risk factors for early recurrence after cryoablation for HCC.
出处 《世界华人消化杂志》 CAS 北大核心 2011年第9期960-963,共4页 World Chinese Journal of Digestology
基金 国家科技支撑计划基金资助项目 No.2007BAI05B06~~
关键词 肝细胞癌 冷冻外科 早期复发 危险因素 Hepatocellular carcinoma Cryosurgery Early recurrence Risk factors
  • 引文网络
  • 相关文献

参考文献18

  • 1NCCN. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. 2010-02; cited 2011-03. Available from: www.nccn.org.
  • 2Orlacchio A, Bazzocchi G, Pastorelli D, Bolacchi F, Angelico M, Almerighi C, Masala S, Simonetti G. Percutaneous cryoablation of small hepatocellular carcinoma with US guidance and CT monitoring: initial experience. Cardiovasc Intervent Radiol 2008; 31: 587-594.
  • 3Weber SM, Lee FT Jr. Expanded treatment of hepatic tumors with radiofrequency ablation and cryoablation. Oncology (Williston Park) 2005; 19: 27-32.
  • 4Mala T. Cryoablation of liver tumours - a review of mechanisms, techniques and clinical outcome. Minim Invasive Ther Allied Technol 2006; 15: 9-17.
  • 5Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430.
  • 6程红岩,徐雯,徐爱民,陈栋,杨业发,贾雨辰.肝动脉插管化疗栓塞在预防肝癌术后复发中的应用价值[J].中华肿瘤杂志,2005,27(10):626-628. 被引量:30
  • 7Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, Reich M, Chan JA, Glickman JN, Ikeda K, Hashimoto M, Watanabe G, Daidone MG, Roayaie S, Schwartz M, Thung S, Salvesen HB, Gabriel S, Mazzaferro V, Bruix J, Friedman SL, Kumada H, Llovet JM, Golub TR. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008; 359: 1995-2004.
  • 8Regimbeau JM, Abdalla EK, Vauthey JN, Lauwers GY, Durand F, Nagorney DM, Ikai I, Yamaoka Y, Belghiti J. Risk factors for early death due to recurrence after liver resection for hepatocellular carcinoma: results of a multicenter study. J Surg Oncol 2004; 85: 36-41.
  • 9Shah SA, Greig PD, Gallinger S, Cattral MS, Dixon E, Kim RD, Taylor BR, Grant DR, Vollmer CM. Factors associated with early recurrence after resection for hepatocellular carcinoma and outcomes. J Am Coll Surg 2006; 202: 275-283.
  • 10Hung IF, Poon RT, Lai CL, Fung J, Fan ST, Yuen MF. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. Am J Gastroenterol 2008; 103: 1663-1673.

二级参考文献20

  • 1Molmenti EP,Klintmalm GB.Liver transplantation in association with hepatocellular carcinoma:an update of the international tumor registry.Liver Transplant,2002,8:736-748.
  • 2Mazzaferro V,Regalia E,Doci R,et al.Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.N Engl J Med,1996,334:693-699.
  • 3Llovet JM,Bruix J.Novel advancements in the management of hepatocellular carcinoma in 2008.J Hepatol,2008,48:S20-S37.
  • 4Matsubara K,Tokino T.Integration of hepatitis B virus DNA and its implications for hepatocarcinogenesis.Mol Biol Med,1990,7:243-260.
  • 5Chen GJ,Yang HI,Su J,et al.Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.JAMA,2006,295:65-73.
  • 6Hung IFN,Poon RT,Lai CL,et al.Recurrence of hepatitis Brelated hepatocellular carcinoma is associated with high viral load at the time of resection.Am J Gastroenterol,2008,103:1663-1673.
  • 7Jang JW,Ghoi JY,Bae SH,et al.The impact of hepatitis B viral load on recurrence after complete necrosis in patients with hepatocellularcarcinomawhoreceivetransarterial chemolipiodolization.Cancer,2007,110:1760-1767.
  • 8Seehofer D,Berg T.Prevention of hepatitis B recurrence after liver transplantation.Transplantation,2005,80:S120-S124.
  • 9Schwartz M,Konstadoulakis M,Roayaie S.Recurrence of hepatocellular carcinoma after liver transplantation:is immunosuppression a factor? Liver Transplant,2005,11:494-496.
  • 10Faria LG,Giqou M,Roque-Afonso AM,et al.Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation.Gastroenterology,2008,134:1890-1899.

共引文献33

同被引文献25

  • 1宋谦,李露嘉,夏放,詹瑛.CT引导下经皮氩氦刀靶向治疗肝癌[J].中国普通外科杂志,2004,13(10):772-773. 被引量:11
  • 2郭志,邢文阁,刘方,于海鹏,李保国,郭秀英,张晟,付丽,邢纪中,张俊义,王友聚,龚彬.氩氦冷冻在原发巨块型肝癌介入治疗中的临床应用[J].中华放射学杂志,2005,39(2):198-203. 被引量:29
  • 3Khatri VP, Chee KG, Petrelli NJ. Modern mulfimo- dality approach to hepatic colorectal metastases: so- lutions and controversies. Surg Onco12007; 16:71-83 [PMID: 17532622 DOI: 10.1016/j.suronc.2007.05.001].
  • 4Ruers TJ, Joosten JJ, Wiering B, Langenhoff BS, Dekker HM, Wobbes T, Oyen WJ, Krabbe PF, Punt CJ. Comparison between local ablative therapy and chemotherapy for non-resectable colorectal liver metastases: a prospective study. Ann Surg Oncol 2007; 14:1161-1169 [PMID: 17195903 DOI: 10.1245/ s10434-006-9312-5].
  • 5Alberts SR. Evolving role of chemotherapy in resect- ed liver metastases. ] Clin Oncol 2006; 24:4952-4953 [PMID: 17075111 DOI: 10.1200/JCO.2006.07.9236].
  • 6Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: re- vised RECIST guideline (version 1.1). Eur ] Cancer 2009; 45:228-247 [PMID: 19097774 DOI: 10.1016/j.ejca.2008.10.026].
  • 7Bonomi AE, Cella DF, Hahn EA, Bjordal K, Sperner- Unterweger B, Gangeri L, Bergman B, Willems- Groot J, Hanquet P, Zittoun R. Multilingual transla- tion of the Functional Assessment of Cancer Ther- apy (FACT) quality of life measurement system. Qual Life Res 1996; 5:309-320 [PMID: 8763799 DOI: 10.1007/BF00433915].
  • 8Moug SJ, Horgan PG. The role of synchronous procedures in the treatment of colorectal liver me- tastases. Surg Oncol 2007; 16:53-58 [PMID: 17517503 DOI: 10.1016/j.suronc.2007.04.005].
  • 9Sabel MS. Cryo-immunology: a review of the lit- erature and proposed mechanisms for stimulatory versus suppressive immune responses. Cryobiol- ogy 2009; 58:1-11 [PMID: 19007768 DOI: 10.1016/ j.cryobiol.2008.10.126].
  • 10Cohen JK, Miller RJ, Ahmed S, Lotz MJ, Baust J. Ten-year biochemical disease control for patients with prostate cancer treated with cryosurgery as primary therapy. Urology 2008; 71:515-518 [PMID: 18342200 DOI: 10.1016/j.urology.2007.09.059].

引证文献3

二级引证文献7

;
使用帮助 返回顶部